First Trust Advisors LP Boosts Holdings in Teladoc Health, Inc. $TDOC

First Trust Advisors LP boosted its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC) by 63.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 350,017 shares of the health services provider’s stock after buying an additional 135,520 shares during the quarter. First Trust Advisors LP’s holdings in Teladoc Health were worth $1,908,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. PNC Financial Services Group Inc. raised its position in Teladoc Health by 202.8% in the first quarter. PNC Financial Services Group Inc. now owns 13,294 shares of the health services provider’s stock worth $72,000 after acquiring an additional 8,903 shares during the period. Jennison Associates LLC grew its position in shares of Teladoc Health by 58.3% during the 1st quarter. Jennison Associates LLC now owns 158,832 shares of the health services provider’s stock valued at $866,000 after acquiring an additional 58,472 shares during the period. Kera Capital Partners Inc. bought a new stake in shares of Teladoc Health during the 1st quarter valued at $90,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Teladoc Health in the 1st quarter worth $1,461,000. Finally, Calamos Wealth Management LLC purchased a new stake in shares of Teladoc Health in the 1st quarter worth $282,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Fernando M. Rodrigues sold 5,677 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the transaction, the insider owned 9,572 shares of the company’s stock, valued at $73,034.36. This represents a 37.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $145,977.16. Following the sale, the chief executive officer owned 389,894 shares of the company’s stock, valued at $2,974,891.22. This represents a 4.68% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 39,195 shares of company stock worth $299,058. 0.70% of the stock is currently owned by corporate insiders.

Teladoc Health Price Performance

TDOC opened at $7.12 on Friday. The company has a 50 day simple moving average of $8.20 and a two-hundred day simple moving average of $6.55. The firm has a market cap of $1.29 billion, a P/E ratio of -7.19 and a beta of 2.12. Teladoc Health, Inc. has a 1-year low of $4.40 and a 1-year high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The firm had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. During the same period last year, the firm earned ($0.19) EPS. The company’s revenue was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities analysts anticipate that Teladoc Health, Inc. will post -0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on TDOC shares. Bank of America lifted their target price on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Citigroup decreased their price objective on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Finally, Canaccord Genuity Group lowered their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $7.54.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.